Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Assessment of Regional Gastrointestinal Absorption of BMS-986165 Using Pharmacoscintigraphic Evaluation in Healthy Male Subjects

The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Body mass index of 18.0 to 32.0 kg/m2, inclusive, and weight ≥ 50 kg, at screening
• Estimated glomerular filtration rate (eGFR) > 80 mL/min/1.732 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula

Exclusion Criteria:

• Any significant acute or chronic medical illness
• Current or recent (within 3 months of study drug administration) disease of the gut that, in the opinion of the Investigator or Medical Monitor, could impact upon the absorption of study drug
• Acute diarrhea, or constipation within 3 weeks prior to randomization
• Any major surgery within 4 weeks of randomization

Other protocol defined inclusion/exclusion criteria could apply